The enzymes DisoNNex and TrypLE are interchangeable as harvesting agents for adipose tissue-derived mesenchymal stromal cells.
Johansen EM., Bangsgaard S., Lethager LL., Højgaard LD., Hu T., Bugge K.
Laboratory Study, published in Cytotherapy (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Cytotherapy (2026)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41762955
- DOI
- 10.1016/j.jcyt.2026.102066
Abstract (original English)
Cell therapies based on adipose tissue-derived mesenchymal stromal cells (ASCs) are promising candidates for the treatment of numerous diseases. Relevant to the potential of these therapies is the development of consistent and efficient ASC-manufacturing processes, with enzymatic cell dissociation being a critical step. DisoNNex, a novel cell dissociation enzyme based mainly on chymotrypsin activity, offers a Good Manufacturing Practice (GMP)-compliant alternative to existing dissociation methods; its impact on ASC characteristics remains yet to be explored. The performance of DisoNNex was compared with the current dissociation industry standard, TrypLE Select Enzyme 1x (TrypLE; Gibco/Thermo Fisher Scientific, Waltham, MA, USA). The DisoNNex concentration matching the dissociation kinetics of TrypLE was defined using time-lapse microscopy and image analysis. ASCs from five donors were harvested using either TrypLE or DisoNNex across two passages. Assays assessed immunophenotype, apoptosis, secretion of vascular endothelial factor, indoleamine 2,3-dioxygenase expression and suppression of lymphocyte proliferation. Multi-omics (bulk RNA sequencing, proteomics, metabolomics and lipidomics) were included in the study. DisoNNex at 15 µg/mL matched TrypLE in dissociation kinetics and maintained ASC viability. No significant differences were observed in functional assays. Multi-omics
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.